Thu, Oct 30, 2014, 1:50 PM EDT - U.S. Markets close in 2 hrs 10 mins


% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

  • dinepat203 dinepat203 Apr 24, 2013 1:15 PM Flag

    As I understand EPOGEN patent expiring next year..So buy Omontys at cheap ?

    This is OLD news but connect the DOTS.....

    Amgen ($AMGN) is preparing to idle production at its only bulk Epogen plant. The Longmont, CO, facility will remain open, handling quality control and process development for other drugs, but some of its 485 workers will lose their jobs.

    An Amgen spokeswoman told the Longmont Times-Call that the shutdown marks a change in the company's manufacturing strategy. The plant will ramp up production of the Epogen active ingredient over the next year or so, and then production there will cease. The spokeswoman says it's not yet clear how many jobs will be cut.

    Other reasons for the stoppage aren't difficult to identify. Epogen and its sister drug Aranesp have never recovered from the safety issues that arose in 2010, when higher doses were linked to all sorts of serious side effects, including death. FDA added warnings to the drugs' labels and Medicare limited reimbursements to discourage the higher doses. But more importantly, Epogen loses its patent protection next year, and now that there's a pathway for biosimilar drugs, it's sure to face competition.

    Starting in 2014, Roche will be allowed to sell their drug Mircera in the US.But the real threat to Amgen's position is the biosimilars
    Omontys, a synthetic pegylated peptidic compound that has the same effect but entails a different approach

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.1199+0.0049(+4.26%)12:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.